` OCUP (Ocuphire Pharma Inc) vs S&P 500 Comparison - Alpha Spread

OCUP
vs
S&P 500

Over the past 12 months, OCUP has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.

Stocks Performance
OCUP vs S&P 500

Loading
OCUP
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
OCUP vs S&P 500

Loading
OCUP
S&P 500
Difference
www.alphaspread.com

Performance By Year
OCUP vs S&P 500

Loading
OCUP
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Ocuphire Pharma Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Ocuphire Pharma Inc
Glance View

Market Cap
35.7m USD
Industry
Pharmaceuticals

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 8 full-time employees. The company went IPO on 2004-11-30. Its products include Nyxol Eye Drops and APX3330. The Nyxol Eye Drops is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including night vision disturbances, reversal of pharmacologically induced mydriasis and presbyopia. The APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases. Its pre-clinical products are APX2009 and APX2014. APX3330 is in Phase II trial for the treatment of patients with diabetic retinopathy (DR), including moderately severe non-proliferative DR and mild proliferative DR, as well as patients with diabetic macular edema (DME) without loss of central vision.

OCUP Intrinsic Value
2.09 USD
Undervaluation 46%
Intrinsic Value
Price
Back to Top